2seventy bio, Inc. (TSVT) Misses Q4 EPS by 17c

2seventy bio, Inc. (NASDAQ: TSVT) reported Q4 EPS of ($0.37), $0.17 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $2.93 million versus the consensus estimate of $13.32 million.

For earnings history and earnings-related data on 2seventy bio, Inc. (TSVT) click here.

You May Also Be Interested In

• Getty Realty (GTY) Reiterated at Market Outperform by Citizens on Investment Volumes
• KB Home (KBH) PT Lowered to $70 at Citizens Amid Higher Rates, Pricing Pressure
• Bernstein SocGen Group Starts Amphenol (APH) at Outperform